Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Revance Therapeutics (RVNC)

Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 437,441
  • Shares Outstanding, K 104,902
  • Annual Sales, $ 234,040 K
  • Annual Income, $ -323,990 K
  • EBIT $ -165 M
  • EBITDA $ -62 M
  • 60-Month Beta 0.95
  • Price/Sales 1.93
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 208.21% ( -29.21%)
  • Historical Volatility 160.37%
  • IV Percentile 91%
  • IV Rank 44.77%
  • IV High 418.92% on 08/07/24
  • IV Low 37.40% on 09/09/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 2,886
  • Volume Avg (30-Day) 2,466
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 40,596
  • Open Int (30-Day) 35,324

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +54.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.36 +18.75%
on 11/11/24
6.09 -34.48%
on 10/28/24
-1.30 (-24.57%)
since 10/18/24
3-Month
3.36 +18.75%
on 11/11/24
6.65 -40.00%
on 08/19/24
-2.63 (-39.73%)
since 08/16/24
52-Week
2.30 +73.48%
on 06/26/24
9.74 -59.06%
on 01/02/24
-3.28 (-45.12%)
since 11/17/23

Most Recent Stories

More News
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

The big pharma company's top drug is losing ground, but its dividend keeps rising.

CVS : 56.05 (+5.38%)
UNH : 589.65 (-0.44%)
ABT : 117.36 (+1.26%)
CI : 322.45 (+0.29%)
AZN : 63.39 (+0.25%)
BGNE : 187.69 (-0.81%)
RVNC : 3.99 (-4.32%)
ABBV : 166.28 (+0.78%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such...

RVNC : 3.99 (-4.32%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such...

RVNC : 3.99 (-4.32%)
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of market. Revance will host a corresponding...

RVNC : 3.99 (-4.32%)
Revance to Participate in the Needham 22nd Annual Healthcare Conference

Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22 nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial...

RVNC : 3.99 (-4.32%)
Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report

Revance Therapeutics, Inc. (RVNC), today announced the release of its 2022 ESG Report, detailing the company’s progress towards its ESG priorities of innovation and access, workplace culture and strong...

RVNC : 3.99 (-4.32%)
Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the following investor conferences.

RVNC : 3.99 (-4.32%)
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor

Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify.

RVNC : 3.99 (-4.32%)
ABBV : 166.28 (+0.78%)
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update

Revance Therapeutics, Inc. (RVNC), today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

RVNC : 3.99 (-4.32%)
Revance Adds Experienced Pharmaceutical Executive to Board of Directors with Appointment of Dr. Vlad Coric, M.D., as Independent Director

Revance Therapeutics, Inc . (RVNC), announced today the appointment of Dr. Vlad Coric, M.D., to its Board of Directors, effective March 1, 2023. Dr. Coric brings more than 22 years of drug development...

RVNC : 3.99 (-4.32%)

Business Summary

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS' peptide technology, which when combined...

See More

Key Turning Points

3rd Resistance Point 4.33
2nd Resistance Point 4.26
1st Resistance Point 4.12
Last Price 3.99
1st Support Level 3.92
2nd Support Level 3.85
3rd Support Level 3.71

See More

52-Week High 9.74
Fibonacci 61.8% 6.90
Fibonacci 50% 6.02
Fibonacci 38.2% 5.14
Last Price 3.99
52-Week Low 2.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar